Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples

Journal of Immunological Methods

Volumn 416, Issue , 2015, Pages 124-136

  Pierog, Piotr ^a   Krishna, Murli ^b   Yamniuk, Aaron ^b   Chauhan, Anil ^c   DeSilva, Binodh ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Anti drug antibodies; Drug specific; Immune complex; Immune complexes; Immunoassays; Immunogenicity

Indexed keywords

ANTIGEN ANTIBODY COMPLEX; DRUG; MONOCLONAL ANTIBODY;

ANIMAL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CIRCULATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG COMPETITION; DRUG EXPOSURE; DRUG SPECIFICITY; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOLOGY; LIMIT OF DETECTION; MACACA FASCICULARIS; METABOLISM; NONHUMAN; PRIORITY JOURNAL; SERUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGEN-ANTIBODY COMPLEX; IMMUNOLOGY; MACACA FASCICULARIS; METABOLISM; PHARMACEUTICAL PREPARATIONS; SERUM;

ANIMALIA; MACACA FASCICULARIS;

EID: 84964301345     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.11.007     Document Type: Article

References (26)

1. Brennan F.R., Morton L.D., Spindeldreher S., Kiessling A., Allenspach R., Hey A., Muller P.Y., Frings W., Sims J. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs 2010, 2:233.
2. Butterfield A.M., Chain J.S., Ackermann B.L., Konrad R.J. Comparison of assay formats for drug-tolerant immunogenicity testing. Bioanalysis 2010, 2:1961.
3. Chirmule N., Jawa V., Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012, 14:296.
4. Eckardt K.U., Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant. 2003, 18:865.
5. Halma C., Daha M.R., van Es L.A. In vivo clearance by the mononuclear phagocyte system in humans: an overview of methods and their interpretation. Clin. Exp. Immunol. 1992, 89:1.
6. Harding F.A., Stickler M.M., Razo J., DuBridge R.B. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010, 2:256.
7. Hart M.H., de Vrieze H., Wouters D., Wolbink G.J., Killestein J., de Groot E.R., Aarden L.A., Rispens T. Differential effect of drug interference in immunogenicity assays. J. Immunol. Methods 2011, 372:196.
8. Heyen J.R., Rojko J., Evans M., Brown T.P., Bobrowski W.F., Vitsky A., Dalton S., Tripathi N., Bollini S.S., Johnson T., Lin J.C., Khan N., Han B. Characterization, biomarkers, and reversibility of a monoclonal antibody-induced immune complex disease in cynomolgus monkeys (Macaca fascicularis). Toxicol. Pathol. 2014, 42(4):765-773.
9. Jefferis R., Lefranc M.P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 2009, 1:332.
10. Kurts C., Panzer U., Anders H.-J., Rees A.J. The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol. 2013, 13:738.
11. Luo Y., Lu Z., Raso S.W., Entrican C., Tangarone B. Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcgamma receptors. MAbs 2009, 1:491.
12. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J. Clin. Invest. 2005, 115:407.
13. Platzer B., Stout M., Fiebiger E. Antigen cross-presentation of immune complexes. Front. Immunol. 2014, 5:140.
14. Schellekens H., Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J. Neurol. 2004, 251(Suppl. 2):II4.
15. Schifferli J.A., Ng Y.C., Estreicher J., Walport M.J. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J. Immunol. 1988, 140:899.
16. Senbagavalli P., Anuradha R., Ramanathan V.D., Kumaraswami V., Nutman T.B., Babu S. Heightened measures of immune complex and complement function and immune complex-mediated granulocyte activation in human lymphatic filariasis. Am. J. Trop. Med. Hyg. 2011, 85:89.
17. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267.
18. Smith K.G., Clatworthy M.R. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 2010, 10:328.
19. Stubenrauch K., Wessels U., Essig U., Vogel R., Schleypen J. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies. J. Pharm. Biomed. Anal. 2010, 52:249.
20. Torosantucci R., Brinks V., Kijanka G., Halim L.A., Sauerborn M., Schellekens H., Jiskoot W. Development of a transgenic mouse model to study the immunogenicity of recombinant human insulin. J. Pharm. Sci. 2014, 103(5):1367-1374.
21. van der Laken C.J., Voskuyl A.E., Roos J.C., Stigter van Walsum M., de Groot E.R., Wolbink G., Dijkmans B.A., Aarden L.A. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:253.
22. Van Hoeyveld E., Bossuyt X. Evaluation of seven commercial ELISA kits compared with the C1q solid-phase binding RIA for detection of circulating immune complexes. Clin. Chem. 2000, 46:283.
23. van Schouwenburg P.A., Bartelds G.M., Hart M.H., Aarden L., Wolbink G.J., Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J. Immunol. Methods 2010, 362:82.
24. van Schouwenburg P.A., Rispens T., Wolbink G.J. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9:164.
25. van Schouwenburg P.A., van de Stadt L.A., de Jong R.N., van Buren E.E., Kruithof S., de Groot E., Hart M., van Ham S.M., Rispens T., Aarden L., Wolbink G.J., Wouters D. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis. 2013, 72:104.
26. Vugmeyster Y., Xu X., Theil F.P., Khawli L.A., Leach M.W. Pharmacokinetics and toxicology of therapeutic proteins: advances and challenges. World J. Biol. Chem. 2012, 3:73.